VANCOUVER, June 25 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased
to announce that iCo's oral Amphotericin B (AmpB) oral formulation "iCo-009"
has been published in a leading journal, The Journal of Infectious Diseases.
The article represents the first ever publication of an oral AmpB eradicating
the parasite responsible for Visceral Leishmaniasis (VL), which affects 12
million people worldwide. Administration of the highest dose of iCo-009
resulted in 99.8% inhibition of the parasite.
AmpB has for many years been the gold standard for systemic antifungal
drugs. AmpB formulated for IV use remains one of the most effective agents in
the treatment of systemic fungal infections, yet no oral formulations are
currently commercially available. Over the past 50 years, many attempts have
been made to formulate AmpB for oral administration, with limited success. The
article indicates that with iCo-009, a self-administered, oral formulation of
AmpB is attainable.
"This is the first peer-reviewed paper to be published demonstrating
eradication of VL with an oral AmpB formulation", stated Andrew Rae, iCo's
President & CEO. "We are excited to be on the forefront of global health by
potentially increasing the quality of life in developing nations. In addition,
iCo-009 may benefit immune compromised patients with cancer, organ transplant
recipients, diabetics and HIV/AIDS in developed nations."
The paper was published in the "Journal of Infectious Diseases" and is
titled "Highly Effective Oral Amphotericin B Formulation against Murine
Visceral Leishmaniasis". The paper was published online on June 22, 2009 and
is available through the Journal of Infectious Diseases website at
Kishor M. Wasan,(1) Ellen K. Wasan,(1,3) Pavel Gershkovich,(1) Xiaohua
Zhu,(4) Richard R. Tidwell,(5) Karl A. Werbovetz,(4) John G. Clement,(2) and
Sheila J. Thornton(1)
(1) Faculty of Pharmaceutical Sciences, University of British Columbia
(2) iCo Therapeutics, Vancouver, BC
(3) School of Health Sciences, British Columbia Institute of Technology,
(4) Division of Medicinal Chemistry and Pharmacognosy, College of
Pharmacy, The Ohio State University, Columbus
(5) Department of Pathology and Lab Medicine, Consortium for Parasitic
Drug Development, University of North Carolina at Chapel Hill, Chapel
Leishmaniasis is a parasite contracted by approximately 2 million people
each year, with 12 million presently infected worldwide, predominantly in the
developing world. If left untreated, Visceral Leishmaniasis can have a
fatality rate of 100% within two years (World Health Organization).
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on
redosing or reformulating drugs with clinical history for new or expanded
indications. iCo has exclusive worldwide rights to three products. iCo-007 is
a second generation antisense candidate licensed from Isis Pharmaceuticals.
iCo-007 is currently in a Phase I trial in Diabetic Macular Edema patients
with compelling early data. iCo-008 is a human monoclonal antibody against
eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune.
iCo-009 is an oral reformulation of a generic anti-fungal and anti-parasitic
intravenous drug licensed from the University of British Columbia. To date,
iCo has reported positive preclinical results for iCo-009. iCo Therapeutics
trades on the TSX-Venture exchange under the symbol "ICO". For more
information, visit the company website at: www.icotherapeutics.com
No regulatory authority has approved or disapproved the content of this
release. The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on iCo
Therapeutics' current beliefs as well as assumptions made by and information
currently available to iCo Therapeutics and relate to, among other things,
anticipated financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo Therapeutics in its
public securities filings; actual events may differ materially from current
expectations. iCo Therapeutics disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information:
For further information: Business Development: Dr. John Clement, CBO,
(778) 688-0644; Finance Contact: Mr. John Meekison, CFO, (604) 602-9414 x 224;
Investor/Media Contact: Frederica Bell, Corp. Devt., (604) 602-9414 x 228; B&D
Capital, Don Mosher, (604) 685-6465